Sparks - Cantargia

Cantargia has announced that the results from its CAN04 trial, assessing nadunolimab in combination with gemcitabine and nab-paclitaxel in advanced/metastatic pancreatic cancer (PDAC), have been published in Clinical Cancer Research, a journal of the American Association for Cancer Research. Highlights of the results included better-than-anticipated efficacy in the 73 treated patients compared to chemotherapy alone, based on historical data. The strongest efficacy was observed in patients with higher levels of IL1RAP, the therapeutic target of nadunolimab, with a median overall survival of 14.2 months reported. Furthermore, safety was found to be acceptable and the level of neuropathy was lower than expected from chemotherapy alone, suggesting a protective effect of nadunolimab. Management is currently preparing for the next stages of clinical development for this programme, a randomised Phase IIb trial with nadunolimab in combination with chemotherapy, which has received regulatory clearance from the US FDA.